The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Clinical trial NCT07386002 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07386002
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2028-12-13
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.